Therapy

Why?

• Patients with unstable angina or non-ST segment elevation MI who receive a glycoprotein IIb/IIIa inhibitors compared with standard medical therapy are less likely to die or have a myocardial infarction, but more likely to have severe bleeding. ^a

Adding glycoprotein IIb/ IIIa inhibitors to standard therapy reduces mortality and further ischaemia

Patient	Treatment	Comparison	Outcome	CER	OR (95% CI)	NNT (95% CI)
unstable angina or non-ST elevation MI   a	glycoprotein IIb/ IIIa inhibitor	standard medical therapy	death or myocardial infarction at 6 months	15%	0.88 (0.81 to 0.95)	65 (41 to 160)
			major bleeding at 6 months	3.6%	1.26 (1.12 to 1.43)	-110 (-240 to -68)